Cancer is the second leading cause of death worldwide, after cardiovascular disease. Its development and progression are often driven by mutations or overactivation of cell signaling pathways, which not only promote tumor growth but also contribute to resistance to therapy. One key pathway implicated in roughly one-third of all solid tumors is the RAS/MAPK pathway, which plays a critical role in cancers such as colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma.
The stock we are bringing to your attention today is that of Erasca Inc. (ERAS), a clinical-stage precision oncology company focused on therapies for RAS- and MAPK pathway-driven cancers. Its lead drug candidates include ERAS-0015, ERAS-4001, and Naporafenib.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.